Lamivudine (BCH-189) salicylate is an orally active nucleoside reverse transcriptase inhibitor (NRTI) that inhibits the reverse transcriptase activity of both HIV-1/2 and hepatitis B virus, while also demonstrating the ability to penetrate the central nervous system [1] [2].